Volume 2 Issue 1
Jan.  2011
Turn off MathJax
Article Contents

doi: 10.3969/j.issn.1674-9081.2011.01.017
  • Received Date: 2010-09-30
  • Publish Date: 2011-01-30
  • loading
  • [1] Jemal A, Siegel R, Xu J, et al.Cancer statistics, 2010[J].CA Cancer J Clin, 2010, 60:277-300. doi:  10.3322/caac.20073
    [2] Isobe T, Herbst RS, Onn A.Current management of advanced non-small cell lung cancer:targeted therapy[J].Semin Oncol, 2005, 32:315-328. doi:  10.1053/j.seminoncol.2005.02.016
    [3] Giaccone G.Epidermal growth factor receptor inhibitors in the treatment of non-small-cell lung cancer[J].J Clin Oncol, 2005, 23:3235-3242. doi:  10.1200/JCO.2005.08.409
    [4] Hsu JY, Wakelee HA.Monoclonal antibodies targeting vascular endothelial growth factor:current status and future challenges in cancer therapy[J].BioDrugs, 2009, 23:289-304. doi:  10.2165/11317600-000000000-00000
    [5] Kakimi K, Nakajima J, Wada H.Active specific immunotherapy and cell-transfer therapy for the treatment of nonsmall cell lung cancer[J].Lung Cancer, 2009, 65:1-8. doi:  10.1016/j.lungcan.2008.10.018
    [6] Raez LE, Fein S, Podack ER.Lung cancer immunotherapy[J].Clin Med Res, 2005, 3:221-228. doi:  10.3121/cmr.3.4.221
    [7] Novellino L, Castelli C, Parmiani G.A listing of human tumor antigens recognized by T cells:March 2004 update[J].Cancer Immunol Immunother, 2005, 54:187-207. doi:  10.1007/s00262-004-0560-6
    [8] Pardoll D.Does the immune system see tumors as foreign or self[J].Annu Rev Immunol, 2003, 21:807-839. doi:  10.1146/annurev.immunol.21.120601.141135
    [9] Hirschowitz EA, Hiestand DM, Yannelli JR.Vaccines for lung cancer[J].J Thorac Oncol, 2006, 1:93-104. doi:  10.1097/01243894-200601000-00019
    [10] Palma M, Choudhury A, Mellstedt H.Cancer vaccines fornon-small-cell lung cancer[J].Minerva Chir, 2009, 64:643-653. http://www.ncbi.nlm.nih.gov/pubmed/20029360
    [11] Dredge K, Marriott JB, Todryk SM, et al.Adjuvants and the promotion of Th1-type cytokines in tumour immunotherapy[J].Cancer Immunol Immunother, 2002, 51:521-531. doi:  10.1007/s00262-002-0309-z
    [12] Pashine A, Valiante NM, Ulmer JB.Targeting the innate immune response with improved vaccine adjuvants[J].Nat Med, 2005, 11:S63-S68. doi:  10.1038/nm1210
    [13] Smyth MJ, Cretney E, Kershaw MH, et al.Cytokines in cancer immunity and immunotherapy[J].Immunol Rev, 2004, 202:275-293. doi:  10.1111/j.0105-2896.2004.00199.x
    [14] Cranmer LD, Trevor KT, Hersh EM.Clinical applications of dendritic cell vaccination in the treatment of cancer[J].Cancer Immunol Immunother, 2004, 53:275-306. doi:  10.1007/s00262-003-0432-5
    [15] Sandler AB, Dubinett SM.COX-2 inhibition and lung cancer[J].Semin Oncol, 2004, 3:45-52. http://www.sciencedirect.com/science/article/pii/S0093775404001915
    [16] Bartlett JB, Dredge K, Dalgleish AG.The evolution of thalidomide and its IMiD derivatives as anticancer agents[J].Nat Rev Cancer, 2004, 4:314-322. doi:  10.1038/nrc1323
    [17] Cross D, Burmester JK.Gene therapy for cancer treatment:past, present and future[J].Clin Med Res, 2006, 4:218-227. doi:  10.3121/cmr.4.3.218
    [18] Kimura H, Yamaguchi Y.A phase Ⅲ randomized study of interleukin-2l ymphokine-activated killer cell immunotherapy combined with chemotherapy or radiotherapy after curative or noncurative resection of primary lung carcinoma[J].Cancer, 1997, 80:42-49. doi:  10.1002/(SICI)1097-0142(19970701)80:1<42::AID-CNCR6>3.0.CO;2-H
    [19] Kimura H, Iizasa T, Ishikawa A, et al.Prospective phase Ⅱ study of post-surgical adjuvant chemo-immunotherapy using autologous dendritic cells and activated killer cells from tissue culture of tumor-draining lymph nodes in primary lung cancer patients[J].Anticancer Res, 2008, 28 (2B) :1229-1238. http://europepmc.org/abstract/MED/18505060
    [20] Garc Garcia B, Neninger E, de la Torre A, et al.Effective inhibition of the epidermal growth factor/epidermal growth factor receptor binding by antiepidermal growth factor anti-bodies is related to better survival in advanced non-small-cell lung cancer patients treated with the epidermal growth factor cancer vaccine[J].Clin Cancer Res, 2008, 14:840-846. doi:  10.1158/1078-0432.CCR-07-1050
    [21] Neninger Vinageras E, de la Torre A, Osorio Rodriguez M, et al.Phase Ⅱ randomized controlled trial of an epidermal growth factor vaccine in advanced non-small-cell lung cancer[J].J Clin Oncol, 2008, 26:1452-1458. doi:  10.1200/JCO.2007.11.5980
    [22] Butts C, Murray N, Maksymiuk A, et al.Randomized phase IIB trial of BLP25 liposome vaccine in stage ⅢB and Ⅳ non-small-cell lung cancer[J].J Clin Oncol, 2005, 23:6674-6681. doi:  10.1200/JCO.2005.13.011
    [23] Butts C, Murray RN, Smith CJ, et al.A multicenter open-label study to assess the safety of a newformulation of BLP25 liposome vaccine in patients with unresectable stage Ⅲ non-small-cell lung cancer[J].Clin Lung Cancer, 2010, 11:391-395. doi:  10.3816/CLC.2010.n.101
    [24] Ramlau R, Westeel V, Papai Z, et al.Randomized phase IIb trial evaluating the therapeutic vaccine TG4010 (MVAMUC1-IL2) as an adjunct to chemotherapy in patients with advanced non-small cell lung cancer (NSCLC) [J].J Thorac Oncol.2008, 3:735-744. doi:  10.1097/JTO.0b013e31817c6b4f
    [25] Shigematsu Y, Hanagiri T, Shiota H, et al.Clinical significance of cancer/testis antigens expression in patients with non-small cell lung cancer[J].Lung Cancer, 2010, 68:105-110. doi:  10.1016/j.lungcan.2009.05.010
    [26] Vansteenkiste J, Zielinski M, Linder A, et al.Final results of a multi-center, double-blind, randomized, placebo-controlled phase Ⅱ study to assess the efficacy of MAGE-A3 immunotherapeutic as adjuvanttherapy in stage ⅠB/Ⅱ non-small cell lung cancer (NSCLC) [J].J Clin Oncol, 2007, 25 (18s) :7554. http://ci.nii.ac.jp/naid/10025557722
    [27] Atanackovic D, Altorki NK, Cao Y, et al.Booster vaccination of cancer patients with MAGE-A3 protein reveals long-term immunological memory or tolerance depending on priming[J].Proc Natl Acad Sci USA, 2008, 105:1650-1655. doi:  10.1073/pnas.0707140104
    [28] Dranoff G, Jaffee E, Lazenby A, et al.Vaccination with irradiated tumor cells engineered to secrete murine granulo-cyte-macrophage colonystimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity[J].Proc Natl Acad Sci USA, 1993, 90:3539-3543. doi:  10.1073/pnas.90.8.3539
    [29] Salgia R, Lynch T, Skarin A, et al.Vaccination with irradiated autologous tumor cells engineered to secrete granulo-cyte-macrophage colonystimulating factor augments antitumor immunity in some patients with metastatic non-small-cell lung carcinoma[J].J Clin Oncol, 2003, 21:624-630. doi:  10.1200/JCO.2003.03.091
    [30] Correale P, Miano ST, Remondo C, et al.Second-line treatment of non small cell lung cancer by biweekly gemcitabine and docetaxel+/- granulocyte-macrophage colony stimulating factor and lowdose aldesleukine[J].Cancer Biol Ther, 2009;8:497-502. doi:  10.4161/cbt.8.6.7593
    [31] Nemunaitis J, Sterman D, Jablons D, et al.Granulocyte-macrophage colony-stimulating factor gene-modified autologous tumor vaccines in non-small-cell lung cancer[J].J Natl Cancer Inst, 2004, 96:326-333. doi:  10.1093/jnci/djh028
    [32] Nemunaitis J, Jahan T, Ross H, et al.Phase1/2 trial of autologous tumor mixed with an allogeneic GVAX vaccine in advanced-stage non-small-cell lung cancer[J].Cancer Gene Ther, 2006, 13:555-562. doi:  10.1038/sj.cgt.7700922
    [33] Kong F, Jirtle RL, Huang DH, et al.Plasma transforming growth factor-beta1 level before radiotherapy correlates with long term outcome of patients with lung carcinoma[J].Cancer1999, 86:1712-1719. doi:  10.1002/(SICI)1097-0142(19991101)86:9<1712::AID-CNCR12>3.0.CO;2-V
    [34] Nemunaitis J, Dillman RO, Schwarzenberger PO, et al.Phase Ⅱ study of belagenpumatucel-L, a transforming growth factor beta-2 antisense gene-modified allogeneic tumor cell vaccine in non-small-cell lung cancer[J].J Clin Oncol, 2006, 24:4721-4730. doi:  10.1200/JCO.2005.05.5335
    [35] Nemunaitis J, Nemunaitis M, Senzer N, et al.Phase Ⅱ trial of Belagenpumatucel-L, a TGF-beta2 antisense gene modified allogeneic tumorvaccine in advanced non small cell lung cancer (NSCLC) patients[J].Cancer Gene Ther, 2009, 16:620-624. doi:  10.1038/cgt.2009.15
  • 加载中


    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Article Metrics

    Article views (132) PDF downloads(5) Cited by()
    Proportional views


    DownLoad:  Full-Size Img  PowerPoint